1. Home
  2. CTNM vs PSTL Comparison

CTNM vs PSTL Comparison

Compare CTNM & PSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • PSTL
  • Stock Information
  • Founded
  • CTNM 2009
  • PSTL 2018
  • Country
  • CTNM United States
  • PSTL United States
  • Employees
  • CTNM N/A
  • PSTL N/A
  • Industry
  • CTNM
  • PSTL Real Estate Investment Trusts
  • Sector
  • CTNM
  • PSTL Real Estate
  • Exchange
  • CTNM Nasdaq
  • PSTL Nasdaq
  • Market Cap
  • CTNM 328.1M
  • PSTL 329.8M
  • IPO Year
  • CTNM 2024
  • PSTL 2019
  • Fundamental
  • Price
  • CTNM $10.90
  • PSTL $15.07
  • Analyst Decision
  • CTNM Strong Buy
  • PSTL Buy
  • Analyst Count
  • CTNM 5
  • PSTL 2
  • Target Price
  • CTNM $22.20
  • PSTL $17.38
  • AVG Volume (30 Days)
  • CTNM 93.7K
  • PSTL 126.5K
  • Earning Date
  • CTNM 11-06-2025
  • PSTL 11-04-2025
  • Dividend Yield
  • CTNM N/A
  • PSTL 6.59%
  • EPS Growth
  • CTNM N/A
  • PSTL 344.13
  • EPS
  • CTNM N/A
  • PSTL 0.39
  • Revenue
  • CTNM N/A
  • PSTL $86,535,000.00
  • Revenue This Year
  • CTNM N/A
  • PSTL $23.94
  • Revenue Next Year
  • CTNM N/A
  • PSTL $10.73
  • P/E Ratio
  • CTNM N/A
  • PSTL $38.02
  • Revenue Growth
  • CTNM N/A
  • PSTL 26.43
  • 52 Week Low
  • CTNM $3.35
  • PSTL $12.26
  • 52 Week High
  • CTNM $20.24
  • PSTL $16.50
  • Technical
  • Relative Strength Index (RSI)
  • CTNM 46.91
  • PSTL 46.59
  • Support Level
  • CTNM $10.77
  • PSTL $14.70
  • Resistance Level
  • CTNM $11.34
  • PSTL $15.41
  • Average True Range (ATR)
  • CTNM 0.66
  • PSTL 0.25
  • MACD
  • CTNM -0.17
  • PSTL -0.00
  • Stochastic Oscillator
  • CTNM 27.31
  • PSTL 57.57

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About PSTL Postal Realty Trust Inc.

Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.

Share on Social Networks: